Full Archive

Bell Ringing

Yesterday morning Dexcom CEO Kevin Sayer rang the opening bell for the Nasdaq later that afternoon Insulet CEO Jim Hollingshead rang the closing bell. Noticeably absent from the podium was Tandem CEO John Sheridan. While Mr. Sayer and Mr. Hollingshead are being cheered by their stakeholders Mr. Sheridan is lucky, he’s not being whacked by Tandem stakeholders. Since taking over as CEO on March 1, 2019, Tandem shares have fallen over...

Talent wins again!

Yes, today is World Diabetes Day which occurs in November which is a month devoted to diabetes. Supposedly the goal of these marketing designed events is to raise awareness. Given that diabetes continues to grow at epidemic rates, that still after the billions spent nearly two thirds of patients are NOT achieving good control it’s difficult to see why we need more awareness. Let’s be honest here folks you can’t...

The Future Will Look Like The Past

Not a day goes by without someone asking me who the third player will be in the CGM market. It won’t be Senseonics nor will be it be Medtronic the two companies besides Dexcom and Abbott to have an FDA approved sensor. Implantable is a bad business model and Medtronic is clueless. And let’s state up front we do not care who has a CE mark it’s FDA approval that...

Who benefits most?

Before we begin today a little shameless self-promotion. My special report The Ozempic Effect The Hype The Hysteria The Truth is shaping up as a best seller. This deep dive into how Ozempic Wegovy Mounjaro will impact not just our wacky world but the world in general is going to be a fascinating read. As with most things we write it will contain actionable information and of course will be...

Let the games begin!

Now that all the major diabetes tech companies have reported it’s safe to say two things. 1. Ozempic is NOT killing diabetes tech. 2. Consolidation is next on the agenda. It’s the second point that needs to examined further. As we noted last week Tandem most likely will be the catalyst for the coming consolidation. With a market cap of just over $1 Billion, sitting on almost $500 million in cash and an...

TGIF

As we head into the weekend, I’ve been trying to come up with new superlatives to describe how Lilly and Novo Nordisk are doing. To say their results were spectacular is an understatement but also not at all surprising. These two longtime rivals are just killing it, and this is just the beginning. Think of where sales will be when they fix their manufacturing issues and reimbursement improves. Not to...

Is this the same market?

Before I get into the earnings released by Insulet this afternoon here’s something to chew on. Tandem closed at $15.20 down another 14.37%. As it stands today this company with almost $500 million in cash and some 440,000 users has a market cap of …. Wait for it … $988 MILLION – think about that just for a moment boys and girls. And as you are about to see it’s...